#United States #New York #Freenome Holdings #Perceptive Capital #Nasdaq PCSC

Perceptive Capital Solutions Corp Postpones Extraordinary General Meeting

On July 9, 2026, Perceptive Capital Solutions Corp (PCSC), a special purpose acquisition company listed on Nasdaq under the ticker PCSC, announced a delay in their upcoming extraordinary general meeting of shareholders. Originally scheduled to take place on the same day, the meeting has now been postponed to July 15, 2026, at 10:00 a.m. Eastern Time.

This change is primarily aimed at allowing additional time for PCSC and Freenome Holdings, Inc., the company with which PCSC intends to merge, to complete necessary disclosures. Freenome specializes in innovative cancer detection technologies, including blood-based screening tests, and is the focus of PCSC’s proposed business combination.

The extraordinary meeting is crucial as shareholders are set to vote on several proposals pertaining to this anticipated merger. By postponing, the company aims to enhance transparency, providing updated information and details about events that have occurred since the initial proxy statement was filed and mailed.

PCSC’s shareholders of record as of June 12, 2026, will be entitled to participate in the rescheduled meeting. Those who have not yet voted or wish to amend their previous votes are encouraged to submit their proxies promptly. Valid proxies previously submitted remain in effect for this postponed meeting, ensuring that shareholder opinions will be fully accounted for.

In addition to the rescheduled general meeting date, PCSC has extended the deadline for shareholders to submit redemption demands concerning the Class A ordinary shares until 5:00 p.m. Eastern Time on July 13, 2026. Shareholders wishing to withdraw their previously submitted demands can do so by contacting the transfer agent. This extension not only provides a timeframe for shareholders to review the upcoming disclosures but also encourages greater participation in the voting process.

Joseph Edelman, Chairman, and Adam Stone, CEO of PCSC, lead a team dedicated to ensuring that all necessary steps are taken for the smooth execution of this business combination. The merger agreement, signed on December 5, 2025, links PCSC and Freenome as they aim to transform cancer diagnostics and enhance testing capabilities.

As the new date of July 15 approaches, stakeholders are reminded to prepare for the significant vote that will shape the future of PCSC and Freenome, formerly known as the StarNet Merger Sub entities involved in this process. As excitement builds, shareholders and interested parties should stay abreast of developments and review the documents filed with the SEC.

In conclusion, the postponement of PCSC’s extraordinary general meeting reflects prudent corporate governance aimed at ensuring that shareholders are fully informed before making pivotal decisions about the merger. With forward-looking statements guiding this venture, both PCSC and Freenome remain committed to executing their vision of advancing health care through innovative solutions in cancer detection.